CSIMarket Company Name, Ticker, Suppliers, else..
 
Inmed Pharmaceuticals Inc  (NASDAQ: INM)
Other Ticker:  
 
 
Price: $1.9550 $-0.15 -6.905%
Day's High: $2.0202 Week Perf: -5.56 %
Day's Low: $ 1.91 30 Day Perf: -28.13 %
Volume (M): 12 52 Wk High: $ 15.70
Volume (M$): $ 23 52 Wk Avg: $4.68
Open: $2.02 52 Wk Low: $1.91



 Market Capitalization (Millions $) 0
 Shares Outstanding (Millions) 0
 Employees 11
 Revenues (TTM) (Millions $) 7
 Net Income (TTM) (Millions $) -3
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 0

Inmed Pharmaceuticals Inc
InMed Pharmaceuticals Inc. is a biopharmaceutical company that focuses on the research and development of cannabinoid-based therapies. The company utilizes its proprietary bioinformatics platform, called INM-101, to identify potential drug targets and develop novel therapies for specific diseases and conditions. InMed's goal is to leverage the therapeutic benefits of cannabinoids to address unmet medical needs in areas such as dermatology, ophthalmology, and pain management. The company is based in Vancouver, British Columbia, Canada, and is listed on the Toronto Stock Exchange.


   Company Address: Suite 310 - 815 W. Hastings Street B.C 0
   Company Phone Number: 669-7207   Stock Exchange / Ticker: NASDAQ INM


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ACAD   -5.57%    
AKBA   -7.55%    
NRIX   -13.5%    
RYTM   -9.43%    
SUPN        0.62% 
YMAB        1.35% 
• View Complete Report
   



Sunshine Biopharma Inc

The Losses have intensified at SBFM amid the fiscal interval ending December 31 2024

SBFM announced in the fourth quarter of 2024 financial report surge in revenue by 24.932 % to $9.59 million from the comparable quarter a year before, but it has increased a loss per share at $-1.11 per share. Sunshine Biopharma Inc s' revenue, surge in the fourth quarter of 2024 compares positively to its Major Pharmaceutical Preparations industry peers, which reported all in all 11.84 % business rise in the same period thus far.

Reviva Pharmaceuticals Holdings Inc

The company reported operating deficit in the fourth quarter of 2024

While the earnings season of the October to December 31 2024 continues, many companies have reported the respective numbers. In the thick of it, have been many constituents of the Major Pharmaceutical Preparations industry. As well as, now, RVPH disclosed operating deficit of $-6.284606 million, for the financial three months closing Dec 31 2024.

Novabay Pharmaceuticals Inc

Novabay Pharmaceuticals Inc reported it had very difficult period, all along the fourth quarter of 2024 earnings season

the Major Pharmaceutical Preparations company announced disappointing fiscal time-frame ending December 31 2024, where Revenue melted down by -40.492 % to $2.01 million and the Novabay Pharmaceuticals Inc posted net deficit per share to $-1.05, relative to $-56.37, in the fiscal time-frame ending December 31 2023. The on averageMajor Pharmaceutical Preparations sector, posted a top-line gain in the fourth quarter of 2024.

Cns Pharmaceuticals Inc

Breaking down fourth quarter of 2024 effort, the company's had

In its fiscal period ending December 31 2024 company lost money at $-31.49 per share, opposite of $-2,630.49 per share a year prior reporting season, In the prior reporting season Cns Pharmaceuticals Inc realized $-12.50 per share.

Phio Pharmaceuticals Corp

In the fiscal span ending December 31 2024 operating shortfall echoed progress to $-1.899 million, at the PHIO

Trailing the bellwethers in the Major Pharmaceutical Preparations sector, a few smaller corporations are publishing the respective results. Phio Pharmaceuticals Corp revealed it has booked operating shortfall of $-1.674 million, for the fourth quarter of 2024.







Inmed Pharmaceuticals Inc's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright � 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com